


New methods to identify personalized drug treatments for breast cancer

March 1 2022



Genomic landscape of PDxOs compared to PDXs and human tumors. a,



Correlation heat map illustrating genome-wide DNA methylation analysis for 11 sets of patient-derived models compared to commonly used breast cancer cell lines. The color scale indicates the Pearson correlation coefficient. b, Eleven sets of models were characterized at different time points (early and late) to assess molecular fidelity with the human tumors. The heat map is divided into four sections from top to bottom: annotations, exome sequencing variant detection, CN correlations from SNP array data and RNA-seq gene expression correlations. Mutation variants are shown with an oncoprint plot highlighting single-nucleotide variants and indels for commonly mutated genes in breast cancer. Quantitative CNV correlations are shown using a heat map of Spearman correlations for gene-level log2 CN ratios. Quantitative transcriptome correlations are shown using a heat map of Spearman correlations for gene-level log10-transformed RNA-Seq by Expectation-Maximization (RSEM) count estimates; NA, not applicable. c, Unsupervised clustering of the same models shown in b, with the PAM50 gene set to classify subtype. Credit: DOI: 10.1038/s43018-022-00337-6

For years, researchers at Huntsman Cancer Institute at the University of Utah (U of U) have honed a process of developing breast cancer models using tumors donated by breast cancer patients, which they then implant into mice as a way to study the tumor's behavior.

Now, the research team reports a new, more efficient way to grow these tumors. In addition, they outline a process to test potential drugs to help prioritize clinical therapy choices based on unique <u>tumor</u> characteristics.

The study, published this week in the journal *Nature Cancer*, creates a way for researchers to narrow the number of drugs that might be effective in each tumor based on its unique characteristics and its behavior in the laboratory models of the cancer. Using this resource, the researchers uncovered experimental and Food and Drug Administration-approved drugs with high efficacy against the models. They extended this work to personalize therapy for a patient with <u>metastatic breast</u>



<u>cancer</u>, which resulted in a complete response for the patient and a progression-free survival period more than three times longer than her previous therapies.

"We were able to utilize the data to prioritize therapy options for a patient," says Alana Welm, Ph.D., co-lead author, breast cancer researcher at Huntsman Cancer Institute, and professor of oncological sciences at the U of U. "While this therapy was unfortunately not curative, it led to regression of the patient's tumor and a longer survival period."

Welm says this unique bank of tumor models is critical to advancing research on aggressive breast cancers. "It is also, to our knowledge, the first time that such models have been used to influence the therapy choice of a breast cancer patient in a clinical trial setting."

The research team included a diverse group of clinicians, laboratory researchers, and technicians from Huntsman Cancer Institute at the University of Utah, Baylor College of Medicine, the Jackson Labs, the University of Connecticut, and the University of Pittsburgh. The team worked together to prioritize advancing research on samples most aligned with current challenges seen in the clinic.

A new clinical trial called FORESEE (NCT04450706) builds on the findings of this study. Led by Saundra Buys, MD, chief of the division of oncology at Huntsman Cancer Institute, the trial tests patient-derived tumor models to inform the treatment selection in metastatic <u>breast</u> cancer patients.

With a second trial in development, Welm says, "We will also use the models to predict recurrence for a subset of newly diagnosed <u>breast</u> <u>cancer</u> patients, and then attempt to personalize therapy for the metastatic stage of the disease when recurrence happens."



More information: Katrin P. Guillen et al, A human breast cancerderived xenograft and organoid platform for drug discovery and precision oncology, *Nature Cancer* (2022). <u>DOI:</u> 10.1038/s43018-022-00337-6

Provided by University of Utah

Citation: New methods to identify personalized drug treatments for breast cancer (2022, March 1) retrieved 20 April 2024 from https://medicalxpress.com/news/2022-03-methods-personalized-drug-treatments-breast.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.